drugset / Trial / NCT01709760

A Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With RA

NCT01709760

Phase 3 Unknown 91 enrolled Mycenax Biotech Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination with Methotrexate versus Methotrexate Alone in Patients with Rheumatoid Arthritis

Timeline

Start
2012-11
Primary completion
2017-12
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg Subcutaneous
Background Methotrexate Small molecule 15 mg
Background Methotrexate Small molecule 25 mg

Indications